Outcome of patients with CML after SCT in the era of tyrosine kinase inhibitors

Bone Marrow Transplantation

Volumn 47, Issue 2, 2012, Pages 304-

  Saussele S ^a   Hehlmann, R ^a   Gratwohl, A ^b   Hochhaus, A ^c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Universitatsklinikum Basel   (Switzerland)

^c JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADVANCED CANCER; ALLOGENEIC STEM CELL TRANSPLANTATION; BLAST CELL CRISIS; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG TREATMENT FAILURE; HUMAN; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT;

EID: 84857031124     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.70     Document Type: Letter

References (5)

1. Venepalli N, Rezvani K, Mielke S, Savani BN. Role of allo-SCT for CML in 2010. Bone Marrow Transplant 2010; 45: 1579-1586.
2. Milojkovic D, Nicholson E, Apperley JF, Holyoake TL, Shepherd P, Drummond MW et al. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haema-tologica 2010; 95: 224-231.
3. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041-6051.
4. Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J et al. Drug treatment is superior to allografting as first line therapy in chronic myeloid leukemia. Blood 2007; 109: 4686-4692. (Pubitemid 46827759)
5. Saussele S, Lauseker M, Gratwohl A, Heim D, Beelen DW, Dohner H et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010; 115: 1880-1885.